Business Wire

ftrack reimagines ftrack Review and launches cineSync 5, the next generation of media review

20.4.2022 19:30:00 EEST | Business Wire | Press release

Share

ftrack, the developer of Academy Award-winning media review and team collaboration solutions for the creative industries, has launched significant updates to two of its flagship offerings: ftrack Review, the browser-based platform for interactive media review, and cineSync, the desktop media review solution heavily utilized by the film and television industries. ftrack Review’s new free-flowing user experience makes for a more lightweight, accessible media review experience for creatives, while cineSync’s fundamental update addresses the evolving needs of VFX studios working today.

Both ftrack Review’s reimagined workflows and cineSync 5 are available to try today. cineSync 5 is available as a free extension for all cineSync 4 Pro users.

ftrack was recently acquired by Backlight, a media technology company serving media, entertainment and video-forward customers with technology solutions that dramatically improve every step of the media content lifecycle. The acquisition allows ftrack to focus on product development and innovation, and provide its customers with the best possible tools and solutions like ftrack Review and cineSync.

ftrack Review Reimagined

ftrack Review introduces a newly updated, modern user interface designed for highly intuitive, user-friendly review sessions, alongside a greater focus on efficiency.

“We’ve listened to our customers’ feedback and have incorporated it into a new ftrack Review update that makes for a more responsive media review experience,” says Rory McGregor, product manager. “Users can now benefit from everything they enjoyed before—including centralized feedback cycles and interactive real-time review—but with the added advantage of a much more effortless workflow. We’re excited to see what our users think as we advance our multifaceted media review ecosystem at ftrack.”

Some of the new features in ftrack Review include:

  • An all-new interface designed to make reviews more free-flowing
  • Faster, more streamlined and responsive reviews with fewer clicks, even when reviewing larger projects with lots of guests and notes
  • A newly designed feedback bar
  • New toolbar features like ghosting, flip and flop, and resolution selection
  • New features for the power user, including tools to manage reviews from within the player interface.

See the complete list of features in ftrack Review’s latest update

ftrack Review's new features are planned to be implemented into ftrack Studio soon—ftrack's full production tracking, shot management, and media review platform

"The latest update to ftrack Review shows that ftrack has listened to our needs and quickly implemented much-valued new features,” says John Valentine, ftrack/workflow coordinator at Blue Zoo Animation Studio, an animation studio known for producing children's television series, advertising commercials, and short films. “With a new, user-friendly UI, an intuitive design layout, and more emphasis on what's being reviewed, it has never been easier for ourselves or our clients to view, comment and review material, we at Blue Zoo are excited by what we've seen and what's coming next."

Introducing cineSync 5

cineSync 5 is built on the legacy of industry-leading cineSync, now reimagined and rebuilt from the ground up to meet the evolving demands of creative review and approval. cineSync 5 streamlines the media review process and supports more collaborative reviews—both local and remote—while still meeting the highest requirements across security and performance that cineSync users have come to expect over the last 17 years.

Some of the new features in cineSync 5 include:

  • A new infrastructure designed to support faster, more responsive reviews
  • Local review without a license via cineSync Play
  • OTIO and OCIO v2 support
  • Frame/image sequence playback and OpenEXR support
  • Enhanced production tracking integrations with ftrack Studio and ShotGrid
  • Localization support
  • A new, modern UI

See the complete list of features in cineSync 5

“We’re excited to share cineSync 5 with our cineSync Pro users so they can get a first taste of the future of cineSync,” says Rory McGregor, product manager. “We’ve improved performance, added new features and workflows, updated our sync servers, and redesigned the UI. With these new features, we’re ushering in a new generation for cineSync—one that will make our users’ collaborative workflows more productive than ever before.”

“cineSync 5 is a significant upgrade on an application that's already the best in class. The killer news was the totally overhauled comparison tool with single-key access to shots, interactive and customizable wipe-line, and 0-100% cross-fades,” said Jake Morrison, VFX supervisor, Thor Love & Thunder. “Bonus points for being able to drag anywhere in the window to scrub back and forth with just a hotkey. I never knew I needed it, but now I use it all the time! Congrats to the cineSync team for an outstanding update to an already indispensable tool. They've clearly listened to their users – every new feature feels like it adds functionality. Grab it!”

Ftrack will showcase cineSync5 and the new ftrack Review later this month at the NAB Show in Las Vegas from April 23 to April 27.

About ftrack

ftrack, a Backlight business, is the creator of ftrack Studio, cineSync, and ftrack Review, the Emmy and Academy Award-winning production tracking, interactive media review, and team collaboration platforms for the creative industries. ftrack’s solutions are designed for producers, supervisors, artists, and pipeline developers and make it easy to seamlessly and securely collaborate with anyone, anywhere. Both ftrack's products and company ethos are founded on the core belief that success results from great teamwork. ftrack has built a talented global team that works with honesty, flexibility, and inclusivity and seeks to build a future where process disappears behind progress. ftrack was founded in 2012 and acquired by Backlight in 2021. ftrack is celebrating its 10th anniversary in 2022. To learn how ftrack is helping creatives meet the ever-increasing demands of creative workflows, please visit ftrack.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Andrew Krepow
Hotwire for ftrack, a Backlight Business
BacklightUS@hotwireglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye